Athira Pharma (ATHA)
(Delayed Data from NSDQ)
$3.30 USD
-0.07 (-2.08%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $3.32 +0.02 (0.61%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Athira Pharma, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 147 | 200 | 254 | 185 | 2 |
Receivables | 2 | 1 | 2 | 1 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 6 | 5 | 6 | 0 |
Total Current Assets | 155 | 208 | 261 | 192 | 2 |
Net Property & Equipment | 3 | 4 | 4 | 3 | 0 |
Investments & Advances | 0 | 45 | 66 | 84 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 0 | 0 | 0 | 0 |
Total Assets | 160 | 258 | 332 | 280 | 2 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 3 | 1 | 1 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 28 | 19 | 8 | 3 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 29 | 21 | 9 | 4 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 2 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 2 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 30 | 23 | 11 | 5 | 5 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 17 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 440 | 429 | 417 | 315 | 1 |
Retained Earnings | -309 | -192 | -96 | -41 | -21 |
Other Equity | 0 | -2 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 130 | 235 | 321 | 274 | -3 |
Total Liabilities & Shareholder's Equity | 160 | 258 | 332 | 280 | 2 |
Total Common Equity | 130 | 235 | 321 | 274 | -20 |
Shares Outstanding | 38.00 | 37.80 | 37.30 | 32.40 | NA |
Book Value Per Share | 3.43 | 6.22 | 8.61 | 8.47 | 0.00 |
Fiscal Year End for Athira Pharma, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 122 | 147 | 173 | 186 |
Receivables | NA | 2 | 2 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 5 | 6 | 6 | 6 |
Total Current Assets | NA | 129 | 155 | 179 | 192 |
Net Property & Equipment | NA | 3 | 3 | 4 | 4 |
Investments & Advances | NA | 0 | 0 | 0 | 10 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 1 |
Total Assets | NA | 133 | 160 | 185 | 208 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 0 | 2 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 25 | 28 | 27 | 21 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 26 | 29 | 29 | 22 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 27 | 30 | 30 | 23 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 442 | 440 | 437 | 435 |
Retained Earnings | NA | -336 | -309 | -282 | -249 |
Other Equity | NA | 0 | 0 | -1 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 107 | 130 | 155 | 185 |
Total Liabilities & Shareholder's Equity | NA | 133 | 160 | 185 | 208 |
Total Common Equity | 0 | 107 | 130 | 155 | 185 |
Shares Outstanding | 38.30 | 38.30 | 38.00 | 38.00 | 37.90 |
Book Value Per Share | 0.00 | 2.79 | 3.43 | 4.07 | 4.88 |